- Home
- XTNT vs TCRX Comparison
XTNT vs TCRX Comparison
Compare XTNT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- TCRX
- Stock Information
- Founded
- XTNT N/A
- TCRX 2018
- Country
- XTNT United States
- TCRX United States
- Employees
- XTNT N/A
- TCRX N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- XTNT Health Care
- TCRX Health Care
- Exchange
- XTNT Nasdaq
- TCRX Nasdaq
- Market Cap
- XTNT 60.9M
- TCRX 67.9M
- IPO Year
- XTNT N/A
- TCRX 2021
- Fundamental
- Price
- XTNT $0.45
- TCRX $1.63
- Analyst Decision
- XTNT Strong Buy
- TCRX Strong Buy
- Analyst Count
- XTNT 1
- TCRX 6
- Target Price
- XTNT $3.00
- TCRX $9.83
- AVG Volume (30 Days)
- XTNT 66.0K
- TCRX 567.5K
- Earning Date
- XTNT 05-14-2025
- TCRX 05-12-2025
- Dividend Yield
- XTNT N/A
- TCRX N/A
- EPS Growth
- XTNT N/A
- TCRX N/A
- EPS
- XTNT N/A
- TCRX N/A
- Revenue
- XTNT $117,267,000.00
- TCRX $2,816,000.00
- Revenue This Year
- XTNT $15.56
- TCRX $47.30
- Revenue Next Year
- XTNT $22.39
- TCRX $74.30
- P/E Ratio
- XTNT N/A
- TCRX N/A
- Revenue Growth
- XTNT 28.44
- TCRX N/A
- 52 Week Low
- XTNT $0.33
- TCRX $1.02
- 52 Week High
- XTNT $0.97
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- XTNT 49.25
- TCRX 58.69
- Support Level
- XTNT $0.34
- TCRX $1.02
- Resistance Level
- XTNT $0.43
- TCRX $1.36
- Average True Range (ATR)
- XTNT 0.05
- TCRX 0.17
- MACD
- XTNT 0.01
- TCRX 0.07
- Stochastic Oscillator
- XTNT 68.75
- TCRX 93.85
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.